Jazz Pharmaceuticals (JAZZ) jumped 4.89% over the past two days after announcing better-than-expected earnings. Quarterly revenues increased 67.7% year over year to $208.3 million. Second-quarter 2013 adjusted earnings of $1 per share were well above the year-ago earnings of 81 cents per share.
With your September 2013 $70.000 calls (JAZZ130921C00070000) now up 101.64%, sell all of your remaining options to lock in these triple-digit percentage gains.
With Jazz Pharmaceuticals (JAZZ) up 40.99% since my initial recommendation on May 13, raise your stop in the stock to $78.30 to lock in at least a 35% gain in the stock.
This content is for paid subscribers only. To gain access subscribe to one of our…
It is hard to find a seasoned investor who doesn’t believe the stock market is…
No one believes a financial disaster can strike… until it’s too late. That’s bizarre, considering…
The Options Industry Council is a resource used to educate investors about the benefits and…
The put-call parity is the relationship that exists between put and call prices of the…
“It’s not a stock market, it’s a market of stocks.” -- “Maxims of Wall Street,”…